Current Landscape in Clinical Drug Repurposing: From Non-Oncology Drugs to New Cancer Applications
Abstract
Drug repurposing builds on pharmacological and safety information already available for an approved drug, but this advantage requires additional studies to establish the biological effect and related mechanisms of action. We conducted a clinically focused review of non-oncology drugs tested as active cancer treatments in interventional studies from 1 January 2021 to 31 July 2026. Randomized trials, phase II-III studies, biomarker-selected cohorts, and studies reporting pharmacokinetics or human target engagement were prioritized. Despite the large number of registered studies, the landscape is still dominated by early-phase, academically sponsored trials. Several widely studied candidates, including metformin, nelfinavir, disulfiram-copper, losartan, and propofol, were negative in randomized evaluations. Conversely, aspirin reduced recurrence in localised colorectal cancer with alterations in the PI3K gene, whilst pre-operative administration of peritumoural lidocaine was associated with improved disease-free survival and overall survival in a randomised trial of breast cancer. Pharmacological insights related to ascorbate in pancreatic cancer and simvastatin in recurrent small-cell lung cancer yielded promising results. Across drug classes, unsuccessful programs were often limited by inadequate exposure, uncertain tumor penetration, absent pharmacodynamic evidence, heterogeneous patient populations, or weak continuity between exploratory and confirmatory development.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.